Drugs / pegrizeprument
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05238493 | Apr 2022 → Jan 2023 | — | Veloxis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02800811 | Apr 2015 → Jun 2016 | disease related to transplantation, rheumatoid arthritis | OSE Immunotherapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04837092 | Jun 2021 → Apr 2025 | — | Nantes University Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07290777 | Jul 2026 → Oct 2028 expected | — | Veloxis Pharmaceuticals | Not yet recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegrizeprument | “BACKGROUND: VEL-101, also known as pegrizeprument, is a monovalent, humanized, anti-CD28 PEGylated monoclonal antibody fragment” PMID 42083151 ↗ May 2026 |
| Known as | FR104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02800811 ↗ |
| Known as | VEL-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05238493 ↗ |
| Action | Inhibit | “FR104, a Novel Antagonist Pegylated Anti-CD28 Fab' Antibody Fragment” NCT04837092 ↗ |
| Modality | Monoclonal antibody | “anti-CD28 PEGylated monoclonal antibody fragment” PMID 42083151 ↗ May 2026 |
| Route | Intravenous | “All FR104 doses are administered intravenously by a slow infusion of at least 30 minutes.” NCT02800811 ↗ |
| Target | CD28 | “Anti-CD28” NCT04837092 ↗ |